Disease
M. pneumoniae causes “atypical” pneumonia.
Important Properties
Mycoplasmas are the smallest free-living organisms; many are as small as 0.3 μm in diameter. Their most striking feature is the absence of a cell wall. As a result, Mycoplasmas stain poorly with Gram stain, and antibiotics that inhibit cell wall (peptidoglycan) synthesis (e.g., penicillins and cephalosporins) are ineffective.
Their outer surface is a flexible cell membrane; hence, these organisms can assume a variety of shapes. Mycoplasmas have the only bacterial membrane that contains cholesterol, a sterol usually found in eukaryotic cell membranes.
Mycoplasmas can be grown in the laboratory on artificial media, but they have complex nutritional requirements, including several lipids. They grow slowly and require at least 1 week to form a visible colony. The colony frequently has a characteristic “fried-egg” shape, with a raised center and a thinner outer edge.
Pathogenesis & Epidemiology
M. pneumoniae, a pathogen only for humans, is transmitted by respiratory droplets. In the lungs, the organism is rod-shaped, with a tapered tip that contains specific proteins that serve as the point of attachment to the respiratory epithelium. The respiratory mucosa is not invaded, but ciliary motion is inhibited and necrosis of the epithelium occurs. The mechanism by which M. pneumoniae causes inflammation is uncertain. It does produce hydrogen peroxide, which contributes to the damage to the respiratory tract cells.
M. pneumoniae has only one serotype and is antigenically distinct from other species of Mycoplasma. Immunity is incomplete, and second episodes of disease can occur. During M. pneumoniae infection, autoantibodies are produced against red cells (cold agglutinins) and brain, lung, and liver cells. These antibodies are involved in some of the extrapulmonary manifestations of infection.
M. pneumoniae infections occur worldwide, with an increased incidence in the winter. This organism is the most common cause of pneumonia in people between the ages of 5 and 15 years. It is responsible for outbreaks in groups with close contacts such as families, military personnel, and college students. It is estimated that only 10% of infected individuals actually get pneumonia. Mycoplasma pneumonia accounts for about 5% to 10% of all community-acquired pneumonia.
Clinical Findings
Mycoplasma pneumonia is one of the most common types of atypical pneumonia. It was formerly called primary atypical pneumonia. (Atypical pneumonia is also caused by Legionella pneumophila [Legionnaires’ disease], Chlamydia pneumoniae, Chlamydia psittaci [psittacosis], Coxiella burnetii [Q fever], and viruses such as such as influenza virus and adenovirus. The term atypical means that a causative bacterium cannot be isolated on routine media in the diagnostic laboratory or that the disease does not resemble pneumococcal pneumonia.)
The onset of Mycoplasma pneumonia is gradual, usually beginning with a nonproductive cough, sore throat, or earache.
Small amounts of whitish, nonbloody sputum are produced. Constitutional symptoms of fever, headache, malaise, and myalgias are pronounced. The paucity of findings on chest examination is in marked contrast to the prominence of the infiltrates seen on the patient’s chest X-ray. The disease resolves spontaneously in 10 to 14 days. In addition to pneumonia, M. pneumoniae also causes bronchitis.
The extrapulmonary manifestations include Stevens-Johnson syndrome, erythema multiforme, mucositis, Raynaud’s phenomenon, cardiac arrhythmias, arthralgias, hemolytic anemia, and neurologic manifestations such as encephalitis and Guillain-Barré syndrome.
Laboratory Diagnosis
Diagnosis is usually not made by culturing sputum samples; it takes at least 1 week for colonies to appear on special media. Culture on regular media reveals only normal flora.
Currently, a polymerase chain reaction (PCR) assay that detects M. pneumoniae-specific nucleic acids in sputum or in respiratory secretions is the best diagnostic procedure.
Serologic testing for the presence of antibodies in the patient’s serum may also be useful. A cold-agglutinin titer of 1:128 or higher is indicative of recent infection. Cold agglutinins are IgM autoantibodies against type O red blood cells that agglutinate these cells at 4°C but not at 37°C. However, only half of patients with Mycoplasma pneumonia will be positive for cold agglutinins. The test is nonspecific; false-positive results occur in influenza virus and adenovirus infections. The diagnosis of M. pneumoniae infection can be confirmed by a fourfold or greater rise in specific antibody titer in either a complement fixation or an enzyme-linked immunosorbent assay (ELISA) test.
Treatment & Prevention The treatment of choice is either a macrolide, such as erythromycin or azithromycin, or a tetracycline, such as doxycycline. The fluoroquinolone levofloxacin is also effective. These drugs can shorten the duration of symptoms, although, as mentioned earlier, the disease resolves spontaneously. Penicillins and cephalosporins are inactive because the organism has no cell wall.
There is no vaccine or other specific preventive measure.